NCT01936870View on ClinicalTrials.gov

Drug Use Investigation for Toviaz

CompletedOBSERVATIONAL

Enrollment

2,521

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

May 19, 2016

Study Completion Date

May 19, 2016

Conditions

Overactive Bladder (OAB)

Interventions

DRUG

Fesoterodine (Toviaz)

Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.